These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23833379)

  • 21. Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection.
    Williams LH; Fleckman P
    Br J Dermatol; 2007 Jan; 156(1):163-4. PubMed ID: 17199585
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
    Benson CA; van der Horst C; Lamarca A; Haas DW; McDonald CK; Steinhart CR; Rublein J; Quinn JB; Mondou E; Rousseau F;
    AIDS; 2004 Nov; 18(17):2269-76. PubMed ID: 15577539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine (3TC)-induced contact dermatitis.
    Smith KJ; Buckley R; Skelton H
    Cutis; 2000 Apr; 65(4):227-9. PubMed ID: 10795085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
    Senanayake TH; Gorantla S; Makarov E; Lu Y; Warren G; Vinogradov SV
    Mol Pharm; 2015 Dec; 12(12):4226-36. PubMed ID: 26565115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamivudine for the treatment of HIV.
    Kumar PN; Patel P
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute generalized exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor.
    Aquilina C; Viraben R; Roueire A
    Arch Intern Med; 1998 Oct; 158(19):2160-1. PubMed ID: 9801185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA; John M; Moore CB; James IR; McKinnon EJ
    AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiretroviral drugs and pregnancy: apropos of an alert regarding mitochondrial pathology and nucleoside analogs].
    Bavoux F; Loubeyre-Unique C; Blanche S
    Arch Pediatr; 2000 May; 7 Suppl 2():407s-408s. PubMed ID: 10904790
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete reversibility of severe nucleoside-induced lipodystrophy.
    Strobel M; Muller P; Claudel P
    AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    Koh MT
    Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
    Lewis W
    Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash.
    Mazhude C; Jones S; Murad S; Taylor C; Easterbrook P
    AIDS; 2002 Jul; 16(11):1566-8. PubMed ID: 12131201
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.